Heather Wakelee, MD
Medical Oncology · Stanford, CANPI 1720137094
Payments from drug & device makers
Across 229 payments — averaging $9263.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$903K
- Genentech, Inc.$660K
- Clovis Oncology, Inc.$101K
- Pfizer$91K
- Seagen Inc.$77K
- Helsinn Healthcare SA$62K
- plus $227K from 16 others
Across 13 payments — averaging $805.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$10K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 49 | $903,292 |
| Genentech, Inc. | 47 | $660,321 |
| Clovis Oncology, Inc. | 3 | $101,040 |
| Pfizer | 20 | $90,813 |
| Seagen Inc. | 38 | $76,797 |
| Helsinn Healthcare SA | 8 | $62,412 |
| Astrazeneca UK Limited | 8 | $55,096 |
| E.r. Squibb & Sons, L.L.C. | 6 | $51,307 |
| AstraZeneca | 11 | $35,655 |
| Roche Products Limited | 5 | $31,059 |
| Chugai Pharmaceutical Co., Ltd. | 7 | $29,511 |
| Novartis | 5 | $9,128 |
| Beone Medicines USA, Inc. | 3 | $4,125 |
| F. Hoffmann-la Roche AG | 3 | $3,174 |
| Daiichi Sankyo Inc. | 4 | $1,786 |
| GSK | 4 | $1,652 |
| Janssen Global Services, LLC | 1 | $1,550 |
| Blueprint Medicines Corporation | 1 | $1,463 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $640 |
| Genentech USA, Inc. | 3 | $298 |
| Johnson & Johnson | 1 | $71 |
| Amgen | 1 | $52 |
How this compares
$2,121,240 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Sandhya SrinivasStanford$10.3M
- Melinda TelliStanford$10.3M
- Ranjana AdvaniStanford$7.6M
- Joel NealStanford$6.3M
- Lipika GoyalStanford$5.4M
- Kristen GanjooStanford$4.8M
- Gabriel MannisStanford$3.6M
- Saad Munib Ahmed KhanStanford$3M
- George SledgeStanford$2.1M
- Christopher ChenStanford$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.